Xi-qi XU, Zhi-cheng JING. The 6th World Symposium on Pulmonary Hypertension: Focus on Updates on Definition and Clinical Classification of Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 197-201. doi: 10.3969/j.issn.1674-9081.2018.03.002
Citation: Xi-qi XU, Zhi-cheng JING. The 6th World Symposium on Pulmonary Hypertension: Focus on Updates on Definition and Clinical Classification of Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 197-201. doi: 10.3969/j.issn.1674-9081.2018.03.002

The 6th World Symposium on Pulmonary Hypertension: Focus on Updates on Definition and Clinical Classification of Pulmonary Hypertension

doi: 10.3969/j.issn.1674-9081.2018.03.002
More Information
  • Corresponding author: XU Xi-qi Tel: 010-88396016, E-mail: xuxiqi0928@163.com
  • Received Date: 2018-03-13
  • Publish Date: 2018-05-30
  • The definition and clinical classification of pulmonary hypertension (PH) were updated in the 6th World Symposium on Pulmonary Hypertension (WSPH). The hemodynamic definition of PH keeps no change, but pre-capillary PH was redefined as mean pulmonary arterial pressure>20 mm Hg, pulmonary artery wedge pressure < 15 mm Hg and pulmonary vessel resistance>3 WU. The updated clinical classification included:pulmonary arterial hypertension(PAH) with vasoreactivity was added as a subclass of PAH; in drugs and toxins induced PAH, the role of methamphetamines and dasatinib was updated from likely to definite; pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis was changed from 1' to a subclass of PAH; splenectomy and thyroid diseases were withdrawn from the group 5 of PH, etc. These clinical practice updates will guide clinical practice better.
  • loading
  • [1] Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62:D34-D41. doi:  10.1016/j.jacc.2013.10.029
    [2] Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects:a systematic review[J]. Eur Respir J, 2009, 34:888-894. doi:  10.1183/09031936.00145608
    [3] McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62:D73-D81. doi:  10.1016/j.jacc.2013.10.034
    [4] Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62:D92-D99. doi:  10.1016/j.jacc.2013.10.024
    [5] Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension[J]. N Engl J Med, 2002, 346:896-903. doi:  10.1056/NEJMoa012212
    [6] Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J, 2016, 37:67-119. doi:  10.1093/eurheartj/ehv317
    [7] Valerio CJ, Schreiber BE, Handler CE, et al. Borderline mean pulmonary artery pressure in patients with systemic sclerosis:transpulmonary gradient predicts risk of developing pulmonary hypertension[J]. Arthritis Rheum, 2013, 65:1074-1084. doi:  10.1002/art.37838
    [8] Douschan P, Kovacs G, Avian A, et al. Mild Elevation of Pulmonary Arterial Pressure as A Predictor of Mortality[J]. Am J Respir Crit Care Med, 2018, 197:509-516. doi:  10.1164/rccm.201706-1215OC
    [9] Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease[J]. Eur Respir J, 2014, 44:1635-1645. doi:  10.1183/09031936.00050114
    [10] Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol, 2009, 54:S43-S54. doi:  10.1016/j.jacc.2009.04.012
    [11] Zamanian RT, Hedlin H, Greuenwald P, et al. Features and Outcomes of Methamphetamine Associated Pulmonary Arterial Hypertension[J]. Am J Respir Crit Care Med, 2018, 197:788-800. doi:  10.1164/rccm.201705-0943OC
    [12] Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension:a population-based study[J]. Eur Respir J, 2017, 50:1700217. doi:  10.1183/13993003.00217-2017
    [13] Montani D, Girerd B, Jaïs X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease:a population-based study[J]. Lancet Respir Med, 2017, 5:125-134. doi:  10.1016/S2213-2600(16)30438-6
    [14] Jaïs X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension[J]. Thorax, 2005, 60:1031-1034. doi:  10.1136/thx.2004.038083
    [15] Freitas CSG, Baldi BG, Jardim C, et al. Pulmonary hypertension in lymphangioleiomyomatosis:prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method[J]. Orphanet J Rare Dis, 2017, 12:74. doi:  10.1186/s13023-017-0626-0
    [16] Richter MJ, Sommer N, Schermuly R, et al. The prognostic impact of thyroid function in pulmonary hypertension[J]. J Heart Lung Transplant, 2016, 35:1427-1434. doi:  10.1016/j.healun.2016.05.022
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Article Metrics

    Article views (371) PDF downloads(429) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return